頁籤選單縮合
題名 | Treatment Outcomes for Hepatoblastoma: Experience of 35 Cases at a Single Institution |
---|---|
作者姓名(外文) | Tsay, Pei-kwei; Lai, Jin-yao; Yang, Chao-ping; Hung, Iou-jih; Hsueh, Chuen; Tsai, Ming-horng; Jaing, Tang-her; | 書刊名 | Journal of the Formosan Medical Association |
卷期 | 110:5 2011.05[民100.05] |
頁次 | 頁322-325 |
分類號 | 416.451 |
關鍵詞 | Hepatoblastoma; Liver surgery; Neoadjuvant chemotherapy; Survival; |
語文 | 英文(English) |
英文摘要 | Background/Purpose Hepatoblastoma is the most common malignant liver tumor in children. Comparative studies have elucidated the optimal pre- or postoperative chemotherapeutic regimens. The aim of this study was to investigate the prognostic significance of baseline tumor characteristics for overall survival and disease-free survival in children with hepatoblastoma. Methods There were 19 male and 16 female children with a median age of 19 months at diagnosis (range: 1–169 months) in our institution between February 1990 and June 2009. We reviewed the clinical presentation, serum α-fetoprotein level at diagnosis, histological subtype, treatment, and outcomes. Results Twenty-seven patients (78%) underwent neoadjuvant chemotherapy. The majority of patients subsequently underwent either hemihepatectomy (56%) or bisegmentectomy (16%). Only six patients underwent extended hepatic resection, and one of them required rescue liver transplantation. During follow-up, six patients died of progressive disease and two of perioperative mortality. Four of the six who died had pulmonary metastases at the time of diagnosis or follow-up. The median survival time was 28 months (range: 1–181 months). Five-year overall survival was 67.7% (95% confidence interval: 52.0–87.8%) and disease-free survival was 60.2% (95% confidence interval: 41.9–86.5%). Conclusion The potential down-staging effect of neoadjuvant chemotherapy on hepatoblastoma might facilitate remission and convert unresectable tumors into operable ones. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。